Marcos Bortz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcos Bortz has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Berenice Freile
Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires, Argentina, Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Argentina., Argentina
5 shared publications - Juan Manuel O'Connor
Instituto Alexander Fleming, Buenos Aires, Argentina
5 shared publications - Federico Waisberg
Oncología Clínica, Instituto Alexander Fleming, Buenos Aires
4 shared publications - Greta Catani
Gastrointestinal Tumors Department, Alexander Fleming Institute, Buenos Aires, Argentina
4 shared publications - Andres Rodriguez
Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires, Argentina.; Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Argentina., Argentina
3 shared publications - Diego Enrico
Instituto Alexander Fleming, Buenos Aires, Argentina
3 shared publications
Latest Publications
- Open Access
Patients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study—The EMOGI-CRC01 Study
Background/Objectives: The BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There is a need for real-world data in low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression-free survival (PFS) and in the first- and second-line setting and sequences of treatment regimens. Methods: We retrospectively analyze patients from ten oncology centers in Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 and July 2023. Results: A total of 161 patients with metastatic CRC and BRAFV600E-mutation. The median age was 58.5 (IQR 47–69), and 21.7% were MMR-deficient (dMMR). Of these patients, 93.8% received first-line treatment. With a median follow-up of 23 months (95% CI 16.5–33.4 months), the median PFS was 9 months (95% CI 7.4–10.5 months). The most common regimen in first line setting was doublet chemotherapy plus anti-VEGF for 49% of the patients. Twenty-six percent of the patients received BRAF inhibitors in the second-line setting, with a median PFS of 5.2 months (95% CI 4.9—NR); the overall response rate (ORR) was 10.5%. Conclusions: This study represents, to the best of our knowledge, the largest published real-world cohort of BRAFV600E-mutated CRC in Latin America. The heterogeneity of the treatments reflects the existence of barriers to access to high-cost drugs in our country. Cooperative efforts are needed to understand the particular characteristics of this subgroup of patients.
Open AccessPatients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study—The EMOGI-CRC01 Study
Background/Objectives: The BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There is a need for real-world data in low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression-free survival (PFS) and in the first- and second-line setting and sequences of treatment regimens. Methods: We retrospectively analyze patients from ten oncology centers in Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 and July 2023. Results: A total of 161 patients with metastatic CRC and BRAFV600E-mutation. The median age was 58.5 (IQR 47–69), and 21.7% were MMR-deficient (dMMR). Of these patients, 93.8% received first-line treatment. With a median follow-up of 23 months (95% CI 16.5–33.4 months), the median PFS was 9 months (95% CI 7.4–10.5 months). The most common regimen in first line setting was doublet chemotherapy plus anti-VEGF for 49% of the patients. Twenty-six percent of the patients received BRAF inhibitors in the second-line setting, with a median PFS of 5.2 months (95% CI 4.9—NR); the overall response rate (ORR) was 10.5%. Conclusions: This study represents, to the best of our knowledge, the largest published real-world cohort of BRAFV600E-mutated CRC in Latin America. The heterogeneity of the treatments reflects the existence of barriers to access to high-cost drugs in our country. Cooperative efforts are needed to understand the particular characteristics of this subgroup of patients.
- Open Access
- 22 January 2025
- Published by MDPI AG in Preprints.org
Patients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study: The EMOGI-CRC01 Study
Background/Objectives: BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There is a need for real-world data in low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression free survival (PFS) and overall survival (OS) in the first-line setting, and sequences of treatment regimens. Methods: We retrospective analyze patients from ten oncology centers in Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 and July 2023. Results: A total of 161 patients with metastatic CRC and BRAFV600E-mutation. The median age was 58.5 (IQR 47-69) and 21.7% were MMR-deficient (dMMR). 93.8% of the patients received first-line treatment. With a median follow-up of 23 months (95% CI 16.5 - 33.4 months), the median OS was 20.6 months (95% CI 18.4 - 29 months) and PFS 9 months (95% CI 7.4 - 10.5 months). The most common regimen was doublet chemotherapy plus anti-VEGF in 49%. 26% received BRAF inhibitors in second line setting. Conclusions: This study represents, to the best of our knowledge, the largest published real-world cohort of BRAFV600E-mutated CRC in Latin America. The heterogeneity in treatments reflect the existence of barriers to access high-cost drugs in our country. Cooperative efforts are needed to understand the particular characteristics of this subgroup of patients.
- 22 January 2025
- Published by MDPI AG in Preprints.org
Open AccessPatients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study: The EMOGI-CRC01 Study
Background/Objectives: BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There is a need for real-world data in low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression free survival (PFS) and overall survival (OS) in the first-line setting, and sequences of treatment regimens. Methods: We retrospective analyze patients from ten oncology centers in Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 and July 2023. Results: A total of 161 patients with metastatic CRC and BRAFV600E-mutation. The median age was 58.5 (IQR 47-69) and 21.7% were MMR-deficient (dMMR). 93.8% of the patients received first-line treatment. With a median follow-up of 23 months (95% CI 16.5 - 33.4 months), the median OS was 20.6 months (95% CI 18.4 - 29 months) and PFS 9 months (95% CI 7.4 - 10.5 months). The most common regimen was doublet chemotherapy plus anti-VEGF in 49%. 26% received BRAF inhibitors in second line setting. Conclusions: This study represents, to the best of our knowledge, the largest published real-world cohort of BRAFV600E-mutated CRC in Latin America. The heterogeneity in treatments reflect the existence of barriers to access high-cost drugs in our country. Cooperative efforts are needed to understand the particular characteristics of this subgroup of patients.
- Open Access
- 16 December 2024
- Published by Asociacion Argentina de Oncologia Clinica in Oncología Clínica
- Vol. 29 (3)
Cáncer Colorrectal En adultos jóvenes: Experiencia mono institucional
Introducción: El cáncer colorrectal (CCR) en adultos jóvenes es una entidad cada vez más prevalente y se estima que en la próxima década 1 de cada 4 pacientes sea menor de 50 años. En nuestro país existen pocos datos de este subgrupo de pacientes. Métodos: Estudio de cohorte retrospectivo, de pacientes atendidos en nuestra institución, con CCR confirmados histológicamente, desde enero 2018 a junio 2023 y con menos de 50 años al momento del diagnóstico. El objetivo primario fue describir las características clínico-patológicas y moleculares en 3 subgrupos: 40-49, 30-39 y ≤ 29 años. Los objetivos secundarios fueron tiempo al diagnóstico, sobrevida global y sobrevida libre de progresión en los distintos subgrupos. Resultados: Se incluyeron 502 pacientes con histología de adenocarcinoma. El 59.8% tenía 40-49 años, 34.8% 30-39 años y 5.4% ≤ 29 años al momento del diagnóstico. Estadios tempranos (61.3%, 57.1% y 59.3%) y localización derecha (22%, 22.8% y 22.2%) fueron similares en los subgrupos. El sexo femenino fue el más prevalente, siendo mayor en ≤ 29 años (59.3%). El estatus de MMR se pudo determinar en el 69.2% y el déficit de proteínas de MMR (MMRd) fue comparable entre los subgrupos, con porcentajes de 8%, 11.4% y 11.1%, respectivamente. Mutaciones germinales fueron encontradas en un 20% de los pacientes.
- 16 December 2024
- Published by Asociacion Argentina de Oncologia Clinica in Oncología Clínica
- Vol. 29 (3)
Open AccessCáncer Colorrectal En adultos jóvenes: Experiencia mono institucional
Introducción: El cáncer colorrectal (CCR) en adultos jóvenes es una entidad cada vez más prevalente y se estima que en la próxima década 1 de cada 4 pacientes sea menor de 50 años. En nuestro país existen pocos datos de este subgrupo de pacientes. Métodos: Estudio de cohorte retrospectivo, de pacientes atendidos en nuestra institución, con CCR confirmados histológicamente, desde enero 2018 a junio 2023 y con menos de 50 años al momento del diagnóstico. El objetivo primario fue describir las características clínico-patológicas y moleculares en 3 subgrupos: 40-49, 30-39 y ≤ 29 años. Los objetivos secundarios fueron tiempo al diagnóstico, sobrevida global y sobrevida libre de progresión en los distintos subgrupos. Resultados: Se incluyeron 502 pacientes con histología de adenocarcinoma. El 59.8% tenía 40-49 años, 34.8% 30-39 años y 5.4% ≤ 29 años al momento del diagnóstico. Estadios tempranos (61.3%, 57.1% y 59.3%) y localización derecha (22%, 22.8% y 22.2%) fueron similares en los subgrupos. El sexo femenino fue el más prevalente, siendo mayor en ≤ 29 años (59.3%). El estatus de MMR se pudo determinar en el 69.2% y el déficit de proteínas de MMR (MMRd) fue comparable entre los subgrupos, con porcentajes de 8%, 11.4% y 11.1%, respectivamente. Mutaciones germinales fueron encontradas en un 20% de los pacientes.
- Open Access
- 23 August 2024
- Published by Asociacion Argentina de Oncologia Clinica in Oncología Clínica
- Vol. 29 (2)
Evaluación de toxicidad relacionada al tiempo en una cohorte de pacientes con cáncer de mama avanzado RH+/HER2- en tratamiento con ribociclib
Introducción: El tratamiento estándar para pacientes con cáncer de mama RH+/HER2- avanzado involucra el uso de un inhibidor de quinasas dependientes de ciclinas 4/6 (iCDK4/6), junto con terapia hormonal. Se ha demostrado la eficacia de ribociclib en sobrevida libre de progresión y sobrevida global. Objetivos: En este estudio se plantea la importancia de evaluar la toxicidad de tiempo, es decir, el tiempo dedicado a la atención médica, en un entorno del mundo real en pacientes con cáncer de mama RH+/HE2- con enfermedad avanzada que se encuentran recibiendo ribociclib. Métodos: Se incluyeron pacientes del Instituto Alexander Fleming y se recopilaron datos a través de historias clínicas electrónicas y cuestionarios. Se excluyeron aquellas con progresión durante el tratamiento o con pérdida de seguimiento. Resultados: Se evaluaron 77 pacientes. La toxicidad de tiempo se tradujo en una mediana de 2 días de contacto con el sistema de salud en un período de 28 días. Esto evidencia que la mayoría de las pacientes que reciben ribociclib mantienen una relación favorable entre el tiempo dedicado al cuidado de la salud y el tiempo en el hogar. El 46.7 % experimentó toxicidades y las hematológicas fueron las más comunes. Conclusión: Si bien hubo una tendencia numérica, no se encontró una relación estadísticamente significativa entre el desarrollo de las toxicidades y la toxicidad de tiempo.
- 23 August 2024
- Published by Asociacion Argentina de Oncologia Clinica in Oncología Clínica
- Vol. 29 (2)
Open AccessEvaluación de toxicidad relacionada al tiempo en una cohorte de pacientes con cáncer de mama avanzado RH+/HER2- en tratamiento con ribociclib
Introducción: El tratamiento estándar para pacientes con cáncer de mama RH+/HER2- avanzado involucra el uso de un inhibidor de quinasas dependientes de ciclinas 4/6 (iCDK4/6), junto con terapia hormonal. Se ha demostrado la eficacia de ribociclib en sobrevida libre de progresión y sobrevida global. Objetivos: En este estudio se plantea la importancia de evaluar la toxicidad de tiempo, es decir, el tiempo dedicado a la atención médica, en un entorno del mundo real en pacientes con cáncer de mama RH+/HE2- con enfermedad avanzada que se encuentran recibiendo ribociclib. Métodos: Se incluyeron pacientes del Instituto Alexander Fleming y se recopilaron datos a través de historias clínicas electrónicas y cuestionarios. Se excluyeron aquellas con progresión durante el tratamiento o con pérdida de seguimiento. Resultados: Se evaluaron 77 pacientes. La toxicidad de tiempo se tradujo en una mediana de 2 días de contacto con el sistema de salud en un período de 28 días. Esto evidencia que la mayoría de las pacientes que reciben ribociclib mantienen una relación favorable entre el tiempo dedicado al cuidado de la salud y el tiempo en el hogar. El 46.7 % experimentó toxicidades y las hematológicas fueron las más comunes. Conclusión: Si bien hubo una tendencia numérica, no se encontró una relación estadísticamente significativa entre el desarrollo de las toxicidades y la toxicidad de tiempo.
- Open Access
- 15 August 2024
- Published by MDPI AG in Preprints.org
Targeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer
Gastroesophageal cancers, are among the most prevalent cancers globally and represent the third leading cause of cancer-related mortality worldwide. Surgical resection remains the primary curative approach for localized and locally advanced stages, but its effectiveness is limited for locally advanced diseases, evidenced by a low 5-year survival rate of around 25%. High relapse rates post-surgery, particularly in western populations, necessitate the use of neoadjuvant, adjuvant, or perioperative strategies involving chemotherapy and radiation to improve surgical outcomes. Neoadjuvant chemoradiation therapy has demonstrated a significant improvement in overall survival. Recent advances have identified several target genes and pathways involved in the pathogenesis and progression of these cancers, leading to the development of targeted drugs, including immunotherapy, anti-HER-2 antibodies, and anti-VEGFR antibodies. These targeted therapies are emerging as promising interventions for better patient outcomes and personalized treatment approaches and therefore could eventually evolve into a novel therapeutic regimen for gastroesophageal cancer.
- 15 August 2024
- Published by MDPI AG in Preprints.org
Open AccessTargeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer
Gastroesophageal cancers, are among the most prevalent cancers globally and represent the third leading cause of cancer-related mortality worldwide. Surgical resection remains the primary curative approach for localized and locally advanced stages, but its effectiveness is limited for locally advanced diseases, evidenced by a low 5-year survival rate of around 25%. High relapse rates post-surgery, particularly in western populations, necessitate the use of neoadjuvant, adjuvant, or perioperative strategies involving chemotherapy and radiation to improve surgical outcomes. Neoadjuvant chemoradiation therapy has demonstrated a significant improvement in overall survival. Recent advances have identified several target genes and pathways involved in the pathogenesis and progression of these cancers, leading to the development of targeted drugs, including immunotherapy, anti-HER-2 antibodies, and anti-VEGFR antibodies. These targeted therapies are emerging as promising interventions for better patient outcomes and personalized treatment approaches and therefore could eventually evolve into a novel therapeutic regimen for gastroesophageal cancer.
- Open Access
- 1 January 2024
- Published by Bioscientifica in Endocrine Oncology
- Vol. 4 (1) , e240028
Time toxicity of lutetium 177 in gastroenteropancreatic neuroendocrine tumours
Objectives: We aim to investigate the time toxicity of patients with gastroenteropancreatic neuroendocrine tumours treated with Lutetium-177 Dotatate in a single institution. Design: This is a retrospective cohort study. Methods: All patients with gastroenteropancreatic neuroendocrine tumours treated with Lutetium-177 Dotatate at the Alexander Fleming Institute were included. Our primary endpoint was to evaluate time toxicity, which accounted for every day that the patient had contact with any department of any healthcare institution. Results: Our cohort included 21 patients with metastatic disease, female sex 86%, and a median age of 55 (IQR 44–63). The primary tumour site was the small intestine in 47.6% of the cases. The median number of previous systemic treatments for advanced disease was two (IQR 2–3). The overall response rate was 19%, and 66.6% had clinical benefit. The median calculated ‘time toxicity’ was 11 days (IQR 8–18), representing 5.7% of the total treatment duration. The main contributors to time toxicity included infusion days, blood draws, radiological scans, and hospitalisations (median of 4 days for each). Conclusion: Lutetium-177 Dotatate treatment for gastroenteropancreatic neuroendocrine tumours was associated with low time toxicity, excellent tolerability, a good response and prolonged PFS, of which the median was not reached in the short follow-up we present. Newer treatments with different mechanisms of action provide longer survival and widen the landscape of choices. Understanding new clinical endpoints is important for the transition into a more modern clinical practice, strengthening personalised and patient-oriented strategies.
- 1 January 2024
- Published by Bioscientifica in Endocrine Oncology
- Vol. 4 (1) , e240028
Open AccessTime toxicity of lutetium 177 in gastroenteropancreatic neuroendocrine tumours
Objectives: We aim to investigate the time toxicity of patients with gastroenteropancreatic neuroendocrine tumours treated with Lutetium-177 Dotatate in a single institution. Design: This is a retrospective cohort study. Methods: All patients with gastroenteropancreatic neuroendocrine tumours treated with Lutetium-177 Dotatate at the Alexander Fleming Institute were included. Our primary endpoint was to evaluate time toxicity, which accounted for every day that the patient had contact with any department of any healthcare institution. Results: Our cohort included 21 patients with metastatic disease, female sex 86%, and a median age of 55 (IQR 44–63). The primary tumour site was the small intestine in 47.6% of the cases. The median number of previous systemic treatments for advanced disease was two (IQR 2–3). The overall response rate was 19%, and 66.6% had clinical benefit. The median calculated ‘time toxicity’ was 11 days (IQR 8–18), representing 5.7% of the total treatment duration. The main contributors to time toxicity included infusion days, blood draws, radiological scans, and hospitalisations (median of 4 days for each). Conclusion: Lutetium-177 Dotatate treatment for gastroenteropancreatic neuroendocrine tumours was associated with low time toxicity, excellent tolerability, a good response and prolonged PFS, of which the median was not reached in the short follow-up we present. Newer treatments with different mechanisms of action provide longer survival and widen the landscape of choices. Understanding new clinical endpoints is important for the transition into a more modern clinical practice, strengthening personalised and patient-oriented strategies.